Desai Amends Aadi Bioscience Stake Filing

TL;DR

Desai updated his Aadi Bioscience stake filing on 10/1/24. Keep an eye on this.

AI Summary

Neil Desai has amended his Schedule 13D filing for Aadi Bioscience, Inc. on October 1, 2024. The filing indicates a change in the beneficial ownership of the company's common stock. Desai is listed with a business address at 17383 Sunset Boulevard, Suite A250, Pacific Palisades, California.

Why It Matters

This filing update from Neil Desai signals a potential shift in control or significant investment in Aadi Bioscience, Inc., which could impact the company's stock price and strategic direction.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership filings can precede significant corporate actions or market movements, warranting close monitoring.

Key Numbers

• 20241001 — Filing Date (Date of the Schedule 13D/A amendment)

Key Players & Entities

• Neil Desai (person) — Filing party and beneficial owner
• Aadi Bioscience, Inc. (company) — Subject company
• 0001422142 (company) — Central Index Key for Aadi Bioscience, Inc.
• 0001878692 (person) — Central Index Key for Neil Desai
• 17383 Sunset Boulevard, Suite A250, Pacific Palisades, California 90272 (address) — Business and mailing address for Neil Desai and Aadi Bioscience, Inc.
• Dan Koeppen (person) — Contact person at Wilson Sonsini Goodrich & Rosati, P.C.
• Wilson Sonsini Goodrich & Rosati, P.C. (company) — Legal counsel for the filing party

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• d883006dsc13da.htm (SC 13D/A) — 31KB
• 0001193125-24-230376.txt ( ) — 33KB

(c) of the Schedule 13D is hereby amended to reflect the following

Item 2(c) of the Schedule 13D is hereby amended to reflect the following: (c) The Reporting Person is the Founder and CEO of Aanastra, Inc., a biopharmaceutical company focused on developing novel RNA therapeutics targeting Tumor Suppressors and Oncogenes. Effective October 1, 2024, the Reporting Person ceased to serve as Executive Chairman of the Issuer. Item4. Purpose of Transaction. The first sentence of paragraph 2 of Item 4 of Schedule 13D is hereby amended and restated as follows: Effective October 1, 2024, the Reporting Person ceased to serve as Executive Chairman of the Issuer but will continue to serve as a member of the board of directors of the Issuer. In his capacity as a director of the Issuer, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Item5. Interest in Securities of the Issuer.

of Schedule 13D is hereby amended to reflect the following

Item 5 of Schedule 13D is hereby amended to reflect the following: (a) As of the date of this Schedule 13D/A, the Reporting Person beneficially owns an aggregate of 2,117,605 shares of Common Stock, or 8.5% of the Issuers outstanding shares of Common Stock. The beneficial ownership percentages used in this Schedule 13D/A are calculated based on a total of 24,614,834 shares of Common Stock outstanding as of August 2, 2024 plus 306,364 shares of Common Stock issuable upon exercise of options exercisable within 60 days of October 1, 2024 held by the Reporting Person. (b) The Reporting Person and the Reporting Persons spouse share voting and dispositive power with respect to 1,811,241 shares of Common Stock owned by the Anishka Irrevocable Trust and the Anishka Family Trust. The Reporting Person has sole voting and dispositive power with respect to options to purchase 467,950 shares of Common Stock. 306,364 of the Reporting Persons options to purchase shares of Common Stock are exercisable within 60 days of October 1, 2024. Of the remaining options to purchase shares of Common Stock (i) 26,042 shares of Common Stock issuable upon the exercise of options vesting evenly on the 8th day of each month through September 8, 2025, (ii) 54,294 shares of Common Stock issuable upon the exercise of options vesting evenly on the first day of each month through April 1, 2026, and (iii) 81,250 shares of Common Stock issuable upon the exercise of options vesting evenly on the first day of each month through January 1, 2027, subject to Dr. Desais continued service through each vesting date. (c) During the past 60 days, the Reporting Person sold 80,000 shares of Common Stock pursuant to a Rule 10b5-1 trading plan. (d) Except as disclosed in Item 2, no person is known to the Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any securities covered by this Schedule 13D/A. (e) Not Applicable. SIGN

View Full Filing

View this SC 13D/A filing on SEC EDGAR